Excavating the pathogenic gene of breast cancer based on high throughput data of tumor and somatic reprogramming

References

• Zoorob RJ, Salemi JL, Mejia De Grubb MC, et al. A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States. Breast Cancer Res Treat. 2019;174(1):237–248.
   PubMed Web of Science ®Google Scholar
• Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89.
   PubMed Web of Science ®Google Scholar
• Zupunski L, Yaumenenka A, Ryzhov A, et al. Breast cancer incidence in the regions of Belarus and Ukraine most contaminated by the Chernobyl accident: 1978 to 2016. Int J Cancer. 2021;148(8):1839-1849.
   Web of Science ®Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(3):310–320.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Mihaly Z, Kormos M, Lanczky A, et al. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat. 2013;140(2):219–232.
   PubMed Web of Science ®Google Scholar
• Yamanaka S. A fresh look at iPS cells. Cell. 2009;137(1):13–17.
   PubMed Web of Science ®Google Scholar
• Riveiro AR, Brickman JM. From pluripotency to totipotency: an experimentalist’s guide to cellular potency. Development. 2020;147(16):dev189845.
   Web of Science ®Google Scholar
• Brochard V, Beaujean N. Somatic reprograming by nuclear transfer. Methods Mol Biol. 2021;2214:109–123.
   PubMedGoogle Scholar
• Krizhanovsky V, Lowe SW. Stem cells: the promises and perils of p53. Nature. 2009;460(7259):1085–1086.
   PubMed Web of Science ®Google Scholar
• Varum S, Rodrigues AS, Moura MB, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One. 2011;6(6):e20914.
   PubMed Web of Science ®Google Scholar
• Semi K, Matsuda Y, Ohnishi K, et al. Cellular reprogramming and cancer development. Int J Cancer. 2013;132(6):1240–1248.
   PubMed Web of Science ®Google Scholar
• Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432(7015):324–331.
   PubMed Web of Science ®Google Scholar
• Goding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014;14(8):568–573.
   PubMed Web of Science ®Google Scholar
• Halley-Stott RP, Gurdon JB. Epigenetic memory in the context of nuclear reprogramming and cancer. Brief Funct Genomics. 2013;12(3):164–173.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–111.
   PubMed Web of Science ®Google Scholar
• Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7(10):791–799.
   PubMed Web of Science ®Google Scholar
• Donovan PJ. High Oct-ane fuel powers the stem cell. Nat Genet. 2001;29(3):246–247.
   PubMed Web of Science ®Google Scholar
• Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998;95(3):379–391.
   PubMed Web of Science ®Google Scholar
• Hochedlinger K, Yamada Y, Beard C, et al. Ectopic expression of Oct- 4blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005;121(3):465–477.
   PubMed Web of Science ®Google Scholar
• Dennis G Jr., Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5): P3.
   Google Scholar
• Wang K, Shan Z, Duan L, et al. iTRAQ-based quantitative proteomic analysis of Yamanaka factors reprogrammed breast cancer cells. Oncotarget. 2017;8(21):34330–34339.
   PubMedGoogle Scholar
• Morgan MA, Shilatifard A. Chromatin signatures of cancer. Genes Dev. 2015;29(3):238–249.
   PubMed Web of Science ®Google Scholar
• Laugesen A, Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell. 2014;14(6):735–751.
   PubMed Web of Science ®Google Scholar
• Park SJ, Kong HK, Kim YS, et al. Inhibition of S-adenosylhomocysteine hydrolase decreases cell mobility and cell proliferation through cell cycle arrest. Am J Cancer Res. 2015;5:2127–2138.
   PubMed Web of Science ®Google Scholar
• Madhavan S, Gusev Y, Singh S, et al. ERRgamma target genes are poor prognostic factors in Tamoxifen-treated breast cancer. J Exp Clin Cancer Res. 2015;34(1):45.
   PubMedGoogle Scholar
• Colak D, Nofal A, Albakheet A, et al. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One. 2013;8(5):e63204.
   PubMed Web of Science ®Google Scholar
• Liu Y, Choi DS, Sheng J, et al. HN1L promotes triple-negative breast cancer stem cells through LEPR-STAT3 pathway. Stem Cell Reports. 2018;10(1):212–227.
   PubMed Web of Science ®Google Scholar
• Jiao X, Hooper SD, Djureinovic T, et al. Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. BMC Genomics. 2013;14(1):165.
   PubMedGoogle Scholar
• Azeez JM, Vini R, Remadevi V, et al. VDAC1 and SERCA3 mediate progesterone-triggered Ca2+ signaling in breast cancer cells. J Proteome Res. 2018;17(1):698–709.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Z, Liu W, et al. Distinct prognostic values of S100 mRNA expression in breast cancer. Sci Rep. 2017;7(1):39786.
   PubMedGoogle Scholar
• Szabo Z, Hamalainen J, Loikkanen I, et al. Sorbitol dehydrogenase expression is regulated by androgens in the human prostate. Oncol Rep. 2010;23:1233–1239.
   PubMed Web of Science ®Google Scholar
• Capaia M, Granata I, Guarracino M, et al. A hnRNP K(-)AR-Related signature reflects progression toward castration-resistant prostate cancer. Int J Mol Sci. 2018;19(7):1920.
   PubMed Web of Science ®Google Scholar
• Lu H, Zhu H. Effect of siRNA-mediated gene silencing of transketolase on A549 lung cancer cells. Oncol Lett. 2017;14:5906–5912.
   PubMed Web of Science ®Google Scholar
• Lin CC, Chen LC, Tseng VS, et al. Malignant pleural effusion cells show aberrant glucose metabolism gene expression. Eur Respir J. 2011;37(6):1453–1465.
   PubMed Web of Science ®Google Scholar
• Uzozie AC, Selevsek N, Wahlander A, et al. Targeted proteomics for multiplexed verification of markers of colorectal tumorigenesis. Mol Cell Proteomics. 2017;16(3):407–427.
   PubMed Web of Science ®Google Scholar
• Guffanti F, Fratelli M, Ganzinelli M, et al. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. Oncotarget. 2018;9(37):24707–24717.
   PubMedGoogle Scholar
• Varadi V, Bevier M, Grzybowska E, et al. Genetic variation in genes encoding for polymerase zeta subunits associates with breast cancer risk, tumour characteristics and survival. Breast Cancer Res Treat. 2011;129(1):235–245.
   PubMed Web of Science ®Google Scholar
• Xu L, Pang Q, Jiang Y, et al. Four novel mutations in the ALPL gene in Chinese patients with odonto, childhood, and adult hypophosphatasia. Biosci Rep. 2018;38(4). DOI:https://doi.org/10.1042/BSR20171377
   Google Scholar
• Dahir KM, Tilden DR, Warner JL, et al. Rare variants in the gene ALPL that cause hypophosphatasia are strongly associated with Ovarian and uterine disorders. J Clin Endocrinol Metab. 2018;103(6):2234–2243.
   PubMed Web of Science ®Google Scholar
• Thangavelu PU, Krenacs T, Dray E, et al. In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion. Clin Epigenetics. 2016;8(1):120.
   PubMedGoogle Scholar
• JingSong H, Hong G, Yang J, et al. siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration. Oncotarget. 2017;8(2):2585–2593.
   PubMedGoogle Scholar
• Lau WM, Doucet M, Stadel R, et al. Enpp1: a potential facilitator of breast cancer bone metastasis. PLoS One. 2013;8(7):e66752.
   PubMed Web of Science ®Google Scholar
• Takahashi RU, Miyazaki H, Takeshita F, et al. Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. Nat Commun. 2015;6(1):7318.
   PubMedGoogle Scholar